OBJECTIVES:  Romanian public health policies must combine information about effective interventions for treatment of recurrent malignant glioma with information about costs’ interventions. METHODS:  Costs of providing health interventions were comparing using the actual Romanian reimbursement list. We compared two treatments for demonstrate that each additional year of life gained from these interventions are equal performing a survival-gain analysis. Cost-effectiveness for the treatment (bevacizumab+irinotecan or dendritic cell immunotherapy-DCI) was estimated using an outcome indicator, survival-gain, that is defined as the difference between observed and predicted mOS. Effectiveness’ differences were concluded using the Mann-Whitney-Wilcoxon Test. RESULTS: The survival gain analysis consisted in identifying fourteen clinical studies with patients with recurrent malignant glioma that received a standard treatment with bevacizumab+irinotecan vs. a very expensive, non-existing treatment in Romania with DCI. The two interventions weren’t defined relative to adverse health events, only with reported median overall survival declared in the included studies. A total of 381 patients were included in our systematic review with 302(79.26%) of them receiving bevacizumab+irinotecan while 79(20.74%) received DCI. 233(77.15%) of the patients receiving bevacizumab plus irinotecan were diagnosed with glioblastoma, while only 69(22.85%) of the patients having grade III gliomas. In the DCI group, 58(73.41%) of the patients had GB while 21(26.59%) patients had grade III gliomas. In comparison, the studies following the bevacizumab+irinotecan protocol reported a mean survival-gain of -0.02±2.00 while the mean survival-gain was -0.01±4.54 for DCI group. We found that DCI compared with bevacizumab plus irinotecan does not improve statistically survival-gain (p=0.535). The costs for a 14 days of treatment with bevacizumab and irinotecan are approx. 2023Euro, whereas DCI that is not avaible in Romania costs about tens of thousands. CONCLUSIONS:  These comparisons of different interventions for the same disease is a clear indication that more health gain is possible by spending resources on the treatment with bevacizumab+irinotecan.